CLINUVEL PHARMACEUTICALS LIMITED — Director's Dealing 2021

Jul 4, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01. Amended 01/01/11.

Name of entity CLINUVEL PHARMACEUTICALS LTD ABN 88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	01 June 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest
	Direct Interest (Ordinary Shares)
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	30 June 2021
No. of securities held prior to change	3,297,996 Ordinary Shares (includes 2,199,810		Ordinary
	Shares beneficially held in the Clinuvel Conditional
	Performance Rights Scheme Trust and the Performance
	Rights Plan Trust)
	1,513,750UnlistedPerformance	Rights	(various
	milestones, expirydate 20/11/2023)
Class	Ordinary Shares
Number acquired	Nil
Number disposed	122,675

Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration	$3,748,582.55
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	3,175,321 Ordinary Shares (includes 2,199,810 Ordinary
	Shares beneficially held in the Clinuvel Conditional
	Performance Rights Scheme Trust and the Performance
	Rights Plan Trust)
	1,513,750UnlistedPerformanceRights(various
	milestones, expiry date 20/11/2023)
Nature of change	On-market sale, representing 3.71% of his holdings. The
Example: on-market trade, off-market trade, exercise of options, issue	disposal of shares is to meet personal commitments and
of securities under dividend reinvestment plan, participation in buy-	annual rebalancing of portfolio.
back	Dr Wolgen does not receive annual fixed equity awards or
	options as part of his remuneration but is eligible to
	exercise Performance Rights conditional on meeting
	certain specified corporate Performance Conditions,
	within a 4-year vesting period, attached to the
	Performance Rights.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed

Page 2

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above No traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to n/a proceed during this period? If prior written clearance was provided, on what date was this n/a provided?

Page 3